Stay updated on RMC-6236 in RAS Mutant Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the RMC-6236 in RAS Mutant Solid Tumors Clinical Trial page.

Latest updates to the RMC-6236 in RAS Mutant Solid Tumors Clinical Trial page
- CheckyesterdayChange DetectedThe locations section has been expanded to add new recruitment sites, bringing the total to 21 locations across multiple states. New sites include Virginia Mason Medical Center in Seattle, WA, along with several other participating centers.SummaryDifference1%

- Check8 days agoChange DetectedA new NEJM publication citation for Daraxonrasib in previously treated advanced RAS-mutant pancreatic cancer has been added, and the page revision tag was updated from v3.5.3 to v3.5.4.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page now displays Revision: v3.5.3, replacing the previous Revision: v3.5.2. This reflects a minor version update to the page.SummaryDifference0.0%

- Check37 days agoChange DetectedFooter revision label updated to Revision: v3.5.2. The previous Revision: v3.5.0 entry was removed.SummaryDifference0.0%

- Check65 days agoChange DetectedAdded revision v3.5.0 and removed revision v3.4.3.SummaryDifference0.0%

- Check72 days agoChange DetectedRevision updated to v3.4.3. Previous revision v3.4.2 was removed.SummaryDifference0.0%

Stay in the know with updates to RMC-6236 in RAS Mutant Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the RMC-6236 in RAS Mutant Solid Tumors Clinical Trial page.